Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

被引:0
|
作者
Zelniker, T. A. [1 ,2 ]
Raz, I. [3 ]
Mosenzon, O. [3 ]
Dwyer, J. P. [4 ]
Heerspink, H. J. L. [5 ]
Cahn, A. [3 ]
Im, K. [1 ,2 ]
Bhatt, D. L. [1 ,2 ]
Leiter, L. A. [6 ]
McGuire, D. K. [7 ]
Wilding, J. P. H. [8 ]
Gause-Nilsson, I. A. M. [9 ]
Langkilde, A. M. [9 ]
Sabatine, M. S. [1 ,2 ]
Wiviott, S. D. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Hadassah Univ, Med Ctr, Jerusalem, Israel
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] Univ Med Ctr Groningen, Groningen, Netherlands
[6] Univ Toronto, Toronto, ON, Canada
[7] Univ Texas Southwestern Med Sch, Dallas, TX USA
[8] Univ Liverpool, Liverpool, Merseyside, England
[9] AstraZeneca, Gothenburg, Sweden
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
192
引用
收藏
页码:54 / 54
页数:1
相关论文
empty
未找到相关数据